CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Navana Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Navana Pharmaceuticals PLC
House 99, Road 4, Block #B, Banani
Phone: +880 255033580p:+880 255033580 DHAKA, 1213  Bangladesh Ticker: NAVANAPHARNAVANAPHAR
Business Summary
Navana Pharmaceuticals PLC., formerly Navana Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. It operates in two segments: Human Health and Veterinary. The Human Health segment is engaged in manufacturing marketing and selling of pharmaceutical products. It produces tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, eye drops, creams, ointments, and others. The Veterinary segment is engaged in manufacturing marketing distributing and selling of veterinary, poultry and fisheries products. The Company's products include Pmec, Stenide Cream, Agonil Cream, Vontac Tablet, Floxacin, Inpen, Osmina, Methebac, Kcit, Ezitor, Droniva, Ospemifene, Ferri Maltol, Lvofloxacin, Nafgal, Esona, Clonipres, Meltix, Diplin, and Arokast, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20246/30/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AnisuzzamanChowdhury 49 12/2/2020
Managing Director, Director JonaidShafiq 61 11/25/2020
Director SayeedAhmed 44
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 4,408 (As of 6/30/2024)
Outstanding Shares: 107,416,217 (As of 9/30/2024)
Stock Exchange: DSE
Fax Number: +880 255033579


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025